Supportive Care in Cancer

, Volume 26, Issue 11, pp 3801–3809 | Cite as

Neuropsychological profiles of breast cancer and brain tumor cohorts in Northeast Ontario, Canada

  • Matias MarianiEmail author
  • Mark William Glister Collins
Original Article



As developments in cancer treatment have improved outcomes, research has increasingly focused on the role of cancer-related cognitive impairment (CRCI) in quality of life for cancer survivors. Impairment profiles have been heterogeneous across studies, necessitating the study of these effects across different cohorts. The purpose of this preliminary study is to compare the memory profiles of Northeast Ontario breast and CNS cancer patients, as there is no literature which exists for profiling CRCI within this largely rural region.


Sixty-three outpatients with breast cancer (n = 32) or CNS tumors (n = 30) at the Northeast Cancer Centre in Sudbury, Canada, were administered a neuropsychological test battery as part of their clinical examination. Domains measured within this study included attention and concentration, processing speed, motor function, language skills, verbal and visual memory, and executive functioning.


Participants with brain tumors scored poorer on most neuropsychological measures than participants with breast cancer. Initial verbal memory for individuals with breast cancer was lower than delayed recall and recognition trials. Trial 1 performance for this group was also negatively correlated with self-reported anxiety scores.


Consistent with the literature, participants with breast cancer obtained higher scores on most test measures than participants with CNC tumors. Breast cancer participants had lower verbal memory scores on initial trials compared to delayed recall, potentially due to relationships with anxiety and attention. Further research into this cohort will strive to gain greater understanding of the patterns of deficits experienced and how these may inform individuals with cancer in other regions.


Cancer Neuropsychology Cognition Memory Brain tumor Breast cancer 



We would like to acknowledge Trevor Carniello, Jessica Diplock, Katherine George and Meghan Grey for their input and recommendations pertaining to the paper. We would also like to acknowledge the Supportive Care Oncology Research Unit of the Northeast Cancer Centre, Health Sciences North for resources and support.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Wefel JS, Schagen SB (2012) Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 12(3):267–275CrossRefGoogle Scholar
  2. 2.
    Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neuro-Oncol 104(3):639–646CrossRefGoogle Scholar
  3. 3.
    Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS (2012) Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Investig 30:135–148CrossRefGoogle Scholar
  4. 4.
    Reid-Arndt SA (2006) The potential for neuropsychology to inform functional outcomes research with breast cancer survivors. NeuroRehabilitation 21:51–64PubMedGoogle Scholar
  5. 5.
    Cheung YT, Tan EH, Chan A (2012) An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer 20:1361–1375CrossRefGoogle Scholar
  6. 6.
    Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39(3):297–304CrossRefGoogle Scholar
  7. 7.
    O’Farrell E, MacKenzie J, Collins B (2013) Clearing the air: a review of our current understanding of “chemo fog”. Curr Oncol Rep 15(3):260–269CrossRefGoogle Scholar
  8. 8.
    Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 26(1):102–113CrossRefGoogle Scholar
  9. 9.
    Wefel JS, Vardy J, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708CrossRefGoogle Scholar
  10. 10.
    Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A (2013) Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psycho-Oncology 22:1517–1527CrossRefGoogle Scholar
  11. 11.
    McDonald B, Conroy SK, Smith DJ, West JD, Saykin AJ (2012) Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain. Behav Immun 30(Supplement):S117–S125Google Scholar
  12. 12.
    Kesler SR, Kent JS, O’Hara R (2011) Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 68(11):1447–1453CrossRefGoogle Scholar
  13. 13.
    Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, Smeets A, Christiaens M, Leemans A, Van Hecke W, Vandenberghe J, Vandenbulcke M, Suaert S (2011) Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 32:480–493CrossRefGoogle Scholar
  14. 14.
    Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Wada N, Imoto S, Murakami K, Uchitomi Y, The Breast Cancer Survivors’ Brain MRI Database Group (2007) Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109(1):146–156CrossRefGoogle Scholar
  15. 15.
    Van Leeuwen RWF, Brundel DHS, Neef C, van Gelder T, Mathijssen J, Burger DM, Jansman FGA (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108:1071–1078CrossRefGoogle Scholar
  16. 16.
    Scoccianti S, Detti B, Cipressi S, Iannalfi A, Franzese C, Biti G (2012) (2012). Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. J Neurooncol 108(2):291–308CrossRefGoogle Scholar
  17. 17.
    Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28(8):1294–1300CrossRefGoogle Scholar
  18. 18.
    Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24(8):1305–1309CrossRefGoogle Scholar
  19. 19.
    Scherling C, Collins B, MacKenzie J, Lepage C, Bielajew C, Smith A (2012) Structural brain differences in breast cancer patients compared to matched controls prior to chemotherapy. Int J Biol 4(2):3–24CrossRefGoogle Scholar
  20. 20.
    Kesler SR, Adams M, Packer M, Rao V, Henneghan AM, Blayney DW, Palesh O (2017) Disrupted brain network functional dynamics and hyper-correlation of structural and functional connectome topology in patients with breast cancer prior to treatment. Brain Behav 7(3):e00643. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wefel JS, Witgert ME, Meyers CA (2008) Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 18:121–131CrossRefGoogle Scholar
  22. 22.
    Asher A (2011) Cognitive dysfunction among cancer survivors. Am J Phys Med Rehabil 90(5):S16–S26CrossRefGoogle Scholar
  23. 23.
    Jean-Pierre P, Winters PC, Ahles TA, Antoni M, Armstrong FD, Penedo F, Lipshultz SE, Miller TL, Fiscella K (2012) Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study. J Oncol Pract 8(1):30–34CrossRefGoogle Scholar
  24. 24.
    Root JC, Ryan E, Barnett G, Andreotti C, Bolutayo K, Ahles T (2014) Learning and memory performance in a cohort of clinically referred breast cancer survivors: the role of attention versus forgetting in patient-reported memory complaints. Psycho-Oncology 24(5):548–555CrossRefGoogle Scholar
  25. 25.
    Hillis AE (2007) Aphasia: progress in the last quarter of a century. Neurology 69:200–213CrossRefGoogle Scholar
  26. 26.
    Kasselimis DS, Simos PG, Economou A, Peppas C, Evdokimidis I, Potagas C (2013) Are memory deficits dependent on the presence of aphasia in left brain damaged patients? Neuropsychologia 51:1773–1776CrossRefGoogle Scholar
  27. 27.
    Correa DD (2010) Neurocognitive function in brain tumors. Curr Neurol Neurosci Rep 10:232–239CrossRefGoogle Scholar
  28. 28.
    Kizilbash AH, Vanderploeg RD, Curtiss G (2002) The effects of depression and anxiety on memory performance. Arch Clin Neuropsychol 17:57–67CrossRefGoogle Scholar
  29. 29.
    O’Jile JR, Schrimsher GW, O’Bryant SE (2006) The relation of self-report of mood and anxiety to CVLT-C, CVLT, and CVLT-2 in a psychiatric sample. Arch Clin Neuropsychol 20:547–553CrossRefGoogle Scholar
  30. 30.
    Kam JWY, Brenner CA, Handy TC, Boyd LA, Liu-Ambrose T, Lim HJ, Hayden S, Campbell KL (2016) Sustained attention abnormalities in breast cancer survivors with cognitive deficits post chemotherapy: an electrophysiological study. Clin Neurophysiol 127:369–378CrossRefGoogle Scholar
  31. 31.
    Morey CC, Bieler M (2012) Visual short-term memory always requires general attention. Psychon Bull Rev 20(1):163–170CrossRefGoogle Scholar
  32. 32.
    Snyder HR (2013) Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 139(1):81–132CrossRefGoogle Scholar
  33. 33.
    Anderson SW, Damasio H, Tranel D (1990) Neuropsychological impairments associated with lesions caused by tumor or stroke. Arch Neurol 47(4):397–405CrossRefGoogle Scholar
  34. 34.
    Gerstenecker A, Nabors LB, Meneses K, Fiveash JB, Marson DC, Cutter G, Martin RC, Meyers CA, Triebel KL (2014) Cognition in patients with newly diagnosed brain metastasis: profiles and implications. J Neuro-Oncol 120:179–185CrossRefGoogle Scholar
  35. 35.
    Derks J, Reijneveld JC, Douw L (2014) Neural network alterations underlie cognitive deficits in brain tumor patients. Curr Opin Oncol 26:627–633CrossRefGoogle Scholar
  36. 36.
    van Dellen E, Douw L, Hillebrand A, Ris-Hilgersom IHM, Schoonheim MM, Baayen JC, De Witt Hamer PC, Velis DN, Klein M, Heimans JJ, Stam CJ, Reijneveld JC (2012) MEG network differences between low- and high-grade glioma related to epilepsy and cognition. PLoS One 7(11):e50122. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, Verhoeven JS, Christiaens M, Vandenberghe J, Vandenbulcke M, Sunaert S (2012) Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 30(2):274–281CrossRefGoogle Scholar
  38. 38.
    Kallenberg K, Goldmann T, Menke J, Strik H, Bock HC, Mohr A, Buhk JH, Frahm J, Dechent P, Knauth M (2014) Abnormalities in the normal appearing white matter of the cerebral hemisphere contralateral to a malignant brain tumor detected by diffusion tensor imaging. Folia Neuropathol 52(3):226–233CrossRefGoogle Scholar
  39. 39.
    Lange M, Rigal O, Clarisse B, Giffard B, Sevin E, Barillet M, Eustache F, Joly F (2014) Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists. Cancer Treatments Rev 40:810–817CrossRefGoogle Scholar
  40. 40.
    Binder LM, Iverson GL, Brooks BL (2009) To err is human: “abnormal” neuropsychological scores and variability are common in healthy adults. Arch Clin Neuropsychol 24:31–49CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Matias Mariani
    • 1
    • 2
    Email author
  • Mark William Glister Collins
    • 1
  1. 1.Supportive Care Oncology Research Unit, Supportive Care UnitNortheast Cancer Centre, Health Sciences NorthSudburyCanada
  2. 2.Mariani and AssociatesSudburyCanada

Personalised recommendations